An Evolving Role for Oral Fluoropyrimidine Drugs
- 15 February 2002
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (4) , 894-896
- https://doi.org/10.1200/jco.2002.20.4.894
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Multicenter Phase II Study of a 28-Day Regimen of Orally Administered Eniluracil and Fluorouracil in the Treatment of Patients With Anthracycline- and Taxane-Resistant Advanced Breast CancerJournal of Clinical Oncology, 2002
- Oral Versus Intravenous Fluoropyrimidines for Advanced Colorectal Cancer: By Either Route, It’s All the SameJournal of Clinical Oncology, 2001
- The Role of Pharmacogenetics and Pharmacogenomics in Cancer Chemotherapy with 5-FluorouracilPharmacology, 2000
- Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator EniluracilJournal of Clinical Oncology, 2000
- Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II studyCancer Chemotherapy and Pharmacology, 1999
- Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Improving Fluorouracil Chemotherapy with Novel Orally Administered FluoropyrimidinesDrugs, 1999
- Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.Journal of Clinical Oncology, 1998
- Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancerAnnals of Oncology, 1996
- 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.Proceedings of the National Academy of Sciences, 1993